These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Profile of Polish patients with primary progressive multiple sclerosis. Brola W; Sobolewski P; Żak M; Flaga S; Fudala M; Siutka D; Kapica K; Chorąży M; Kułakowska A; Perenc A; Bartosik-Psujek H; Psujek M; Głąbiński A; Pawełczyk M; Gacek S; Potemkowski A Mult Scler Relat Disord; 2019 Aug; 33():33-38. PubMed ID: 31146082 [TBL] [Abstract][Full Text] [Related]
4. Employment and absenteeism in working-age persons with multiple sclerosis. Salter A; Thomas N; Tyry T; Cutter G; Marrie RA J Med Econ; 2017 May; 20(5):493-502. PubMed ID: 28035846 [TBL] [Abstract][Full Text] [Related]
5. Serious infections in patients with relapsing and progressive forms of multiple sclerosis: A German claims data study. Knapp R; Hardtstock F; Krieger J; Wilke T; Maywald U; Chognot C; Muros-Le Rouzic E; Craveiro L Mult Scler Relat Disord; 2022 Dec; 68():104245. PubMed ID: 36306609 [TBL] [Abstract][Full Text] [Related]
6. Increased socioeconomic burden in patients with primary progressive multiple sclerosis: A Danish nationwide population-based study. Blinkenberg M; Kjellberg J; Ibsen R; Magyari M Mult Scler Relat Disord; 2020 Nov; 46():102567. PubMed ID: 33296969 [TBL] [Abstract][Full Text] [Related]
8. Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: The impact of immune-related genes variability. Kiselev I; Bashinskaya V; Baulina N; Kozin M; Popova E; Boyko A; Favorova O; Kulakova O Mult Scler Relat Disord; 2019 Apr; 29():130-136. PubMed ID: 30711878 [TBL] [Abstract][Full Text] [Related]
9. Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey. Hadjimichael O; Vollmer T; Oleen-Burkey M; Health Qual Life Outcomes; 2008 Nov; 6():100. PubMed ID: 19014588 [TBL] [Abstract][Full Text] [Related]
10. Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Tutuncu M; Tang J; Zeid NA; Kale N; Crusan DJ; Atkinson EJ; Siva A; Pittock SJ; Pirko I; Keegan BM; Lucchinetti CF; Noseworthy JH; Rodriguez M; Weinshenker BG; Kantarci OH Mult Scler; 2013 Feb; 19(2):188-98. PubMed ID: 22736750 [TBL] [Abstract][Full Text] [Related]
11. Impact of multiple sclerosis phenotypes on burden of disease in Finland. Purmonen T; Hakkarainen T; Tervomaa M; Ruutiainen J J Med Econ; 2020 Feb; 23(2):156-165. PubMed ID: 31617776 [No Abstract] [Full Text] [Related]
12. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis. Iwanowski P; Losy J; Kramer L; Wójcicka M; Kaufman E J Neurol Sci; 2017 Sep; 380():22-26. PubMed ID: 28870573 [TBL] [Abstract][Full Text] [Related]
13. Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis. Ratzer R; Søndergaard HB; Christensen JR; Börnsen L; Borup R; Sørensen PS; Sellebjerg F Mult Scler; 2013 Dec; 19(14):1841-8. PubMed ID: 24085340 [TBL] [Abstract][Full Text] [Related]
14. Natural history of primary progressive multiple sclerosis. Ebers GC Mult Scler; 2004 Jun; 10 Suppl 1():S8-13; discussion S13-5. PubMed ID: 15218804 [TBL] [Abstract][Full Text] [Related]
15. Cognitive impairment in a population-based study of patients with multiple sclerosis: differences between late relapsing-remitting, secondary progressive and primary progressive multiple sclerosis. Planche V; Gibelin M; Cregut D; Pereira B; Clavelou P Eur J Neurol; 2016 Feb; 23(2):282-9. PubMed ID: 25903918 [TBL] [Abstract][Full Text] [Related]
16. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study. Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736 [TBL] [Abstract][Full Text] [Related]
17. Primary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome. Kantarci OH; Lebrun C; Siva A; Keegan MB; Azevedo CJ; Inglese M; Tintoré M; Newton BD; Durand-Dubief F; Amato MP; De Stefano N; Sormani MP; Pelletier D; Okuda DT Ann Neurol; 2016 Feb; 79(2):288-94. PubMed ID: 26599831 [TBL] [Abstract][Full Text] [Related]
18. Cognitive reserve and symptom experience in multiple sclerosis: a buffer to disability progression over time? Schwartz CE; Quaranto BR; Healy BC; Benedict RH; Vollmer TL Arch Phys Med Rehabil; 2013 Oct; 94(10):1971-81. PubMed ID: 23727344 [TBL] [Abstract][Full Text] [Related]
19. Cognitive impairment differs between primary progressive and relapsing-remitting MS. Ruet A; Deloire M; Charré-Morin J; Hamel D; Brochet B Neurology; 2013 Apr; 80(16):1501-8. PubMed ID: 23516324 [TBL] [Abstract][Full Text] [Related]
20. Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity? Antel J; Antel S; Caramanos Z; Arnold DL; Kuhlmann T Acta Neuropathol; 2012 May; 123(5):627-38. PubMed ID: 22327362 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]